About Myonexus Therapeutics
Myonexus Therapeutics is a company based in Columbus (United States) founded in 2017 by Michael Triplett was acquired by Sarepta in May 2018.. Myonexus Therapeutics has raised $2.5 million across 1 funding round from investors including Sarepta Therapeutics, CincyTech and Rev1 Ventures. Myonexus Therapeutics operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Columbus, United States
- Founders Michael Triplett
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$2.5 M (USD)
in 1 rounds
-
Latest Funding Round
$2.5 M (USD), Seed
Dec 13, 2017
-
Investors
Sarepta Therapeutics
& 4 more
-
Employee Count
Employee Count
-
Acquired by
Sarepta
(May 03, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Myonexus Therapeutics
Myonexus Therapeutics has successfully raised a total of $2.5M through 1 strategic funding round. The most recent funding activity was a Seed round of $2.5 million completed in December 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Seed — $2.5M
-
First Round
First Round
(13 Dec 2017)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2017 | Amount | Seed - Myonexus Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Myonexus Therapeutics
Myonexus Therapeutics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Sarepta Therapeutics, CincyTech and Rev1 Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
CincyTech is engaged in venture capital investments for innovative startups.
|
Founded Year | Domain | Location | |
|
Startup Studio building companies in the US & Europe and Angel Network for Ohio based companies
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Myonexus Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Myonexus Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Myonexus Therapeutics Comparisons
Competitors of Myonexus Therapeutics
Myonexus Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Provider of cell therapies to treat cancer and hematologic conditions
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Myonexus Therapeutics
Frequently Asked Questions about Myonexus Therapeutics
When was Myonexus Therapeutics founded?
Myonexus Therapeutics was founded in 2017.
Where is Myonexus Therapeutics located?
Myonexus Therapeutics is headquartered in Columbus, United States. It is registered at Columbus, Ohio, United States.
Who is the current CEO of Myonexus Therapeutics?
Michael Triplett is the current CEO of Myonexus Therapeutics. They have also founded this company.
Is Myonexus Therapeutics a funded company?
Myonexus Therapeutics is a funded company, having raised a total of $2.5M across 1 funding round to date. The company's 1st funding round was a Seed of $2.5M, raised on Dec 13, 2017.
What does Myonexus Therapeutics do?
Myonexus Therapeutics was founded in 2017 in Columbus, United States, focusing on the gene therapy sector. Treatments for Limb-girdle muscular dystrophy types 2D, 2B, 2E, 2L, and 2C are being advanced, with research based at Nationwide Childrens Hospital. The lead candidate MYO-102, targeting alpha-sarcoglycan for LGMD2D, is in Phase 12a trials. FDA approval has been granted for Phase 12a trials of MYO-101 for LGMD2E via systemic IV delivery.
Who are the top competitors of Myonexus Therapeutics?
Myonexus Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Who are Myonexus Therapeutics's investors?
Myonexus Therapeutics has 5 investors. Key investors include Sarepta Therapeutics, CincyTech, Rev1 Ventures, Jain Foundation, and Gfbonlus.